PedAM
Pediatric Disease Annotations & Medicines
| Disease | prostate cancer |
| Phenotype | C0006142|breast cancer |
| Sentences | 10 |
| PubMedID- 23418847 | The prevalence was particularly high for breast cancer, melanoma of the skin, prostate cancer and bowel cancer. |
| PubMedID- 25368673 | In addition to pancreatic and breast cancer, the incidence of colorectal cancer and prostate cancer is increased in type 2 diabetes. |
| PubMedID- 23629668 | But, similar to breast cancer, anti-angiogenic therapy of prostate cancer has shown only moderate to disappointing effects, with little or no improvement in os resulting from addition of bevacizumab to a standard docetaxel and prednisone therapeutic regimen [64]. |
| PubMedID- 24469255 | Inter-gender differences revealed significantly lower bt values for the prostate cancer compared with the female breast cancer cohort, changes over the course of time could not be found. |
| PubMedID- 23559597 | Rgsl1 was down-regulated, and its function is to increase the gtpase activity of the gαsubunit to attenuate signaling from the g-protein-coupled receptor, located in 1q25.3, the prostate cancer region (hpc1) associated with breast cancer and prostate cancer [33]. |
| PubMedID- 24351742 | López-otín and diamandis [9] compared female breast cancer with male prostate cancer and highlighted several similar features and characteristics; one similarity is that both are hormonally regulated. |
| PubMedID- 26236408 | There is a recognised association of breast cancer with prostate cancer within some families which has been highlighted within several epidemiological studies [21–23]. |
| PubMedID- 26180594 | breast cancer (8 out of 20) and prostate cancer (6 out of 20) are the most frequently studied cancer types; two other studies examined colorectal cancer; three examined gastric cancer; one examined liver cancer; and one examined lung cancer. |
| PubMedID- 21598023 | 2.4; p < 0.01) were reported among breast cancer survivors compared with prostate cancer survivors. |
| PubMedID- 25811344 | The breakthrough report, of the ability of the androgen receptor splice variant mutation, detected in circulating tumor cells, to predict lack of response to abiraterone or enzalutamide, and the remarkable responses of poly(adp-ribose) polymerase inhibitors in prostate cancer with breast cancer genes 1 and 2 (brca1/2) mutations, have elevated hopes of a bright future in the biomarker-driven therapeutic arena. |
Page: 1